Metagenomics and Human Microbiome Analysis

The field includes 263 companies, with Illumina, Oxford Nanopore Technologies and Thermo Fisher Scientific among the named sequencing players. Clinical Microbiomics ApS provides contract research services focused on microbiome analysis, including profiling methods and studies of microbial composition and engraftment. These examples span sequencing tools and specialist analysis services.

Examples among the 21 listed startups are Clinical Microbiomics ApS, Cryptobiotix SA and Phase Genomics. Clinical Microbiomics provides microbiome research services; Cryptobiotix develops gastrointestinal models to test how compounds affect gut communities; Phase Genomics uses proximity-ligation metagenomics to link resistance genes to microbial hosts. They represent distinct service, modeling and analysis approaches.

The Chinese Academy of Sciences CAS is a prominent research organization, with 1,091 documents in the defined window, while the University of California has 405. Other active groups include Sun Yat Sen University, Fudan University and the University of Chinese Academy of Sciences. Their work spans microbial ecology, disease associations, genome-resolved analysis and functional profiling.

Recorded totals include 577 grants worth $465,450,924 since 2020 and 29 funding rounds worth $2,005,094,685. These are aggregate figures, not a measure of funding available to a particular company or project. They should also be distinguished from individual awards, whose relevance to microbiome research may vary.

Illumina and SNIPR TECHNOLOGIES Ltd lead the listed patent holders, with 5 patents each in the defined window. The Regents of The University of California and Zoe Ltd have 4 each, followed by California Institute of Technology with 3. These counts identify the leading holders in the supplied patent data, not the full scope of their intellectual property.

No: patent activity declined by 50% in the defined 24-month window, with 105 patents recorded. This contrasts with publication activity, which grew by 13.6% in the last 12 months. The divergence suggests research output is expanding faster than patenting, though the figures describe activity trends rather than commercial readiness.

Recent examples include a resistant-starch study published in September 2026 and the metastrand framework reported in August 2026. The former examined distinct, reversible gut microbiome changes; the latter combined strand-aware metatranscriptomics with metagenomics to study microbial transcription. Recent multi-omics work also targets small microbial proteins that standard annotation can overlook.

Applications include infectious disease and resistance, gastrointestinal disorders, metabolic health and nutrition, reproductive and infant health, oral health, and skin health and personal care. Infectious disease and resistance is a major area, with 5,035 documents in the data; gastrointestinal disorders has 2,568. These applications range from disease characterization to studying microbial responses to diet and treatment.

The United States and China lead the listed countries, with 34,675 and 33,936 documents respectively. They account for 33.3% and 32.6% of the recorded activity. The United Kingdom follows with 10,375 documents, while Germany has 7,122. These figures describe document activity, not the location of every research collaboration or commercial deployment.